Jefferies analyst Michael Yee maintained a Buy rating on Kodiak Sciences (KOD – Research Report) yesterday and set a price target of $15.00. The company’s shares closed yesterday at $4.90.
Yee covers the Healthcare sector, focusing on stocks such as Biogen, Moderna, and Amarin. According to TipRanks, Yee has an average return of 0.0% and a 47.68% success rate on recommended stocks.
Kodiak Sciences has an analyst consensus of Hold, with a price target consensus of $10.00.
See today’s best-performing stocks on TipRanks >>
Based on Kodiak Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $77.04 million. In comparison, last year the company had a net profit of $0
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Read More on KOD:
